Investors Purchase Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading on Wednesday. Investors purchased 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average volume of 53 put options.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Maravai LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $5.38.

Institutional Trading of Maravai LifeSciences

Institutional investors have recently made changes to their positions in the stock. Sprott Inc. purchased a new stake in shares of Maravai LifeSciences during the 3rd quarter valued at about $29,000. Virtu Financial LLC purchased a new position in Maravai LifeSciences during the fourth quarter valued at $34,000. Insigneo Advisory Services LLC purchased a new position in Maravai LifeSciences during the fourth quarter valued at $34,000. Quantessence Capital LLC purchased a new position in Maravai LifeSciences during the third quarter valued at approximately $31,000. Finally, Stifel Financial Corp purchased a new position in Maravai LifeSciences during the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock opened at $3.50 on Thursday. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $899.75 million, a P/E ratio of -3.89 and a beta of 0.43. The stock’s 50 day moving average is $3.17 and its 200 day moving average is $3.35. Maravai LifeSciences has a twelve month low of $1.66 and a twelve month high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%.The company had revenue of $49.87 million for the quarter, compared to the consensus estimate of $49.06 million. On average, equities research analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.